Compare MVIS & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MVIS | LITS |
|---|---|---|
| Founded | 1993 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.0M | 36.3M |
| IPO Year | 2010 | 2003 |
| Metric | MVIS | LITS |
|---|---|---|
| Price | $1.38 | $1.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 352.3K |
| Earning Date | 10-28-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.91 | 13.81 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $664,000.00 | N/A |
| Revenue This Year | $1,017.55 | N/A |
| Revenue Next Year | $48.15 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.23 | $0.69 |
| 52 Week High | $4.90 | $2.26 |
| Indicator | MVIS | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 44.28 |
| Support Level | $0.56 | $1.12 |
| Resistance Level | $1.89 | $1.26 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 67.05 | 14.71 |
Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars. Geographically, the company operates in United States, Germany, and Other foreign countries.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.